A Polyvalent Cellular Vaccine Induces T-cell Responses Against Specific Self-antigens Overexpressed in Chronic Lymphocytic B-cell Leukemia
暂无分享,去创建一个
[1] E. Kremmer,et al. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70 , 2007, Journal of Translational Medicine.
[2] Christian Adam,et al. Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine , 2007, Journal of Translational Medicine.
[3] P. Kokhaei,et al. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. , 2007, Experimental hematology.
[4] M. Hallek,et al. Dendritic cell-based immunogens for B-cell chronic lymphocytic leukemia. , 2007, Cancer letters.
[5] C. Mayr,et al. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. , 2005, Blood.
[6] R. Gangnus,et al. Vaccination against B-cell chronic lymphocytic leukemia with trioma cells: preclinical evaluation. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] H. Wigzell,et al. Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia. , 2003, Blood.
[8] P. Moss,et al. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. , 2002, Blood.
[9] H. Döhner,et al. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. , 2002, Blood.
[10] S. Endres,et al. Apoptotic Pancreatic Tumor Cells Are Superior to Cell Lysates in Promoting Cross-Priming of Cytotoxic T Cells and Activate NK and γδ T Cells , 2002 .
[11] A. Dieckmann,et al. Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells. , 2002, Blood.
[12] A. Pettitt,et al. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. , 2001, Blood.
[13] E. Cesarman,et al. Telomerase activity in B‐cell non‐Hodgkin lymphoma , 2000, Cancer.
[14] M. Röcken,et al. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. , 2000, Cancer research.
[15] F. caligaris-Cappio,et al. Biology of chronic lymphocytic leukemia. , 2000, Reviews in clinical and experimental hematology.
[16] L. Hültner,et al. Gene therapy of B‐cell lymphoma with cytokine gene‐modified trioma cells , 1999, International journal of cancer.
[17] E. Kimby,et al. Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. , 1999, Blood.
[18] E. Kremmer,et al. Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype , 1999, Gene Therapy.
[19] H. Kantarjian,et al. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. , 1998, Cancer research.
[20] S. Thierfelder,et al. Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity. , 1997, Cancer research.
[21] P. Coulie. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? , 1997, Molecular medicine today.
[22] M. Rottenberg,et al. Bcl‐2, Bax and p53 expression in B‐CLL in relation to in vitro survival and clinical progression , 1996, International journal of cancer.
[23] L. Zitvogel,et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.
[24] B. Leber,et al. Telomerase activity in normal leukocytes and in hematologic malignancies. , 1995, Blood.
[25] T. Kinoshita,et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. , 1994, Blood.
[26] C. Mayr,et al. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes. , 2006, Experimental hematology.
[27] Achim Leutz,et al. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1 , 2006, Nature Genetics.
[28] C. Croce,et al. ATM mutations in B-cell chronic lymphocytic leukemia. , 1999, Cancer research.
[29] P. Heußner,et al. Non-Hodgkin-Lymphome niedriger Malignität , 1995 .
[30] John Calvin Reed,et al. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. , 1993, Blood.